Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

The trial subjects were adults with either type 1 or type 2 diabetes, exhibiting central involvement in diabetic macular ...

We note that the path leading to the FDA approval for Iluvien has been anything but smooth for Alimera. In Oct 2013, the company received the third Complete Response Letter (CRL) from the FDA on ...

“From a creative standpoint, the campaign was focused on bringing light to having something like Iluvien and how that would be beneficial to their lifestyle,” Hoffman said. “If you are dealing with ...

In ANI's New Day trial, patients were randomized to an induction phase to receive either a single Iluvien injection or a series of five monthly injections of aflibercept, followed by supplemental ...

In the A and B arms of the phase 3 FAME study, 956 patients with diabetic macular edema (DME) were randomized to receive either 0.5 µg/day of Iluvien (Alimera Sciences), 0.2 µg/day of Iluvien or ...

ATLANTA — The U.S. Food and Drug Administration has issued a complete response letter to Alimera Sciences for its investigational sustained drug delivery system Iluvien, effectively denying ...

Iluvien will be available as a 0.19mg sustained-release intravitreal implant in a single-use preloaded applicator. It is expected to be available in the 1st quarter of 2015. For more information ...

About ILUVIEN ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant, injected into the back of the eye.

The U.S.-based NEW DAY clinical trial enrolled 306 patients with diabetic macular edema who received a single Iluvien ...

The first time the FDA took a close look at Alimera's application for Iluvien, regulators came back looking for 36-month safety and efficacy data. In its second take on Friday, the agency concluded ...

Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the ...